USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS
The paper presents a review of an update on the comparative pharmacoeconomic analysis of using dimethyl fumarate in the treatment of multiple sclerosis (MS) in European countries. A pharmacoeconomic evaluation was made to study the use of first-line oral dimethyl fumarate versus another first-line o...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2016-12-01
|
| Series: | Неврология, нейропсихиатрия, психосоматика |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/681 |
| _version_ | 1797876418492760064 |
|---|---|
| author | V. R. Mkrtchyan L. V. Brylev I. A. Shpak A. M. Sergeev |
| author_facet | V. R. Mkrtchyan L. V. Brylev I. A. Shpak A. M. Sergeev |
| author_sort | V. R. Mkrtchyan |
| collection | DOAJ |
| description | The paper presents a review of an update on the comparative pharmacoeconomic analysis of using dimethyl fumarate in the treatment of multiple sclerosis (MS) in European countries. A pharmacoeconomic evaluation was made to study the use of first-line oral dimethyl fumarate versus another first-line oral teriflunomide in the treatment of MS in the Russian Federation (for 1 year) and second-line natalizumab and fingolimod. Among first-line oral drugs, dimethyl fumarate was shown to be superior to teriflunomide in a cost-effectiveness ratio and to be slightly ahead of the MS-modifying drugs (MSMDs) and the second-line drugs natalizumab and fingolimod. According to clinical and economic indicators, dimethyl fumarate is the drug of choise among other MSMDs in the treatment of MS. |
| first_indexed | 2024-04-10T02:02:53Z |
| format | Article |
| id | doaj.art-473861a89f4e4d20834aaef0692ffc05 |
| institution | Directory Open Access Journal |
| issn | 2074-2711 2310-1342 |
| language | Russian |
| last_indexed | 2024-04-10T02:02:53Z |
| publishDate | 2016-12-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Неврология, нейропсихиатрия, психосоматика |
| spelling | doaj.art-473861a89f4e4d20834aaef0692ffc052023-03-13T08:42:16ZrusIMA-PRESS LLCНеврология, нейропсихиатрия, психосоматика2074-27112310-13422016-12-01849810310.14412/2074-2711-2016-4-98-103614USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSISV. R. Mkrtchyan0L. V. Brylev1I. A. Shpak2A. M. Sergeev3Z.P. Solovyev Research and Practical Psychoneurology Center, Moscow Healthcare DepartmentZ.P. Solovyev Research and Practical Psychoneurology Center, Moscow Healthcare Department; V.M. Buyanov City Clinical HospitalZ.P. Solovyev Research and Practical Psychoneurology Center, Moscow Healthcare DepartmentInstitute of Applied Economic Researches, Russian Presidential Academy of National Economy and Public AdministrationThe paper presents a review of an update on the comparative pharmacoeconomic analysis of using dimethyl fumarate in the treatment of multiple sclerosis (MS) in European countries. A pharmacoeconomic evaluation was made to study the use of first-line oral dimethyl fumarate versus another first-line oral teriflunomide in the treatment of MS in the Russian Federation (for 1 year) and second-line natalizumab and fingolimod. Among first-line oral drugs, dimethyl fumarate was shown to be superior to teriflunomide in a cost-effectiveness ratio and to be slightly ahead of the MS-modifying drugs (MSMDs) and the second-line drugs natalizumab and fingolimod. According to clinical and economic indicators, dimethyl fumarate is the drug of choise among other MSMDs in the treatment of MS.https://nnp.ima-press.net/nnp/article/view/681multiple sclerosispharmacoeconomicsdimethyl fumarateteriflunomidefingolimodnatalizumab |
| spellingShingle | V. R. Mkrtchyan L. V. Brylev I. A. Shpak A. M. Sergeev USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS Неврология, нейропсихиатрия, психосоматика multiple sclerosis pharmacoeconomics dimethyl fumarate teriflunomide fingolimod natalizumab |
| title | USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS |
| title_full | USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS |
| title_fullStr | USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS |
| title_full_unstemmed | USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS |
| title_short | USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS |
| title_sort | use of dimethyl fumarate in the treatment of multiple sclerosis clinical and economic analysis |
| topic | multiple sclerosis pharmacoeconomics dimethyl fumarate teriflunomide fingolimod natalizumab |
| url | https://nnp.ima-press.net/nnp/article/view/681 |
| work_keys_str_mv | AT vrmkrtchyan useofdimethylfumarateinthetreatmentofmultiplesclerosisclinicalandeconomicanalysis AT lvbrylev useofdimethylfumarateinthetreatmentofmultiplesclerosisclinicalandeconomicanalysis AT iashpak useofdimethylfumarateinthetreatmentofmultiplesclerosisclinicalandeconomicanalysis AT amsergeev useofdimethylfumarateinthetreatmentofmultiplesclerosisclinicalandeconomicanalysis |